You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GW642444

Showing 1 - 25 of 77
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pulmonary Disease, Chronic Obstructive Trial in United States (Placebo, GSK233705/GW642444)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • Mobile, Alabama
  • +11 more
Aug 18, 2020

Asthma Trial (FF/UMEC/VI, ELLIPTA, FF/VI)

Not yet recruiting
  • Asthma
  • (no location specified)
Feb 24, 2023

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (GW642444, Placebo)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GW642444
  • Placebo
  • Camperdown, New South Wales, Australia
  • +13 more
Mar 7, 2018

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • 125/25 mcg once-daily GSK573719/GW642444
  • +2 more
  • Mobile, Alabama
  • +53 more
Apr 30, 2018

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (FF/GW642444 Inhalation Powder, FF Inhalation Powder, GW642444

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • FF/GW642444 Inhalation Powder
  • +3 more
  • Mobile, Alabama
  • +131 more
Jun 14, 2018

Asthma Trial in Worldwide (FF/VI via ELLIPTA DPI, FF via ELLIPTA DPI)

Completed
Has Results
  • Asthma
  • FF/VI via ELLIPTA DPI
  • FF via ELLIPTA DPI
  • Hoover, Alabama
  • +183 more
Sep 12, 2022

Pulmonary Disease, Chronic Obstructive Trial in London (GSK233705, GW642444, GSK233705 and GW642444)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • London, United Kingdom
    GSK Investigational Site
Oct 2, 2017

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719/GW642444 125/25
  • +5 more
  • Jasper, Alabama
  • +52 more
Jan 18, 2018

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • FF/GW642444 Inhalation Powder
  • GW642444 Inhalation Powder
  • Birmingham, Alabama
  • +182 more
Aug 2, 2018

Pulmonary Disease, Chronic Obstructive Trial in United States (Fluticasone Furoate (FF)/GW642444 Inhalation Powder, )

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • Fluticasone Furoate (FF)/GW642444 Inhalation Powder
  • placebo
  • DeLand, Florida
  • +7 more
Oct 9, 2017

Pulmonary Disease, Chronic Obstructive Trial in United States (500mcg/25mcg once daily, Placebo once daily)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • 500mcg/25mcg once daily
  • Placebo once daily
  • Chester, South Carolina
  • +3 more
Oct 9, 2017

Asthma Trial in Worldwide (Fluticasone Furoate/GW642444, Fluticasone propionate)

Completed
Has Results
  • Asthma
  • Fluticasone Furoate/GW642444
  • Fluticasone propionate
  • Oxford, Alabama
  • +46 more
Jan 18, 2018

Pulmonary Disease, Chronic Obstructive Trial in London (GW642444)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • GW642444
  • London, United Kingdom
    GSK Investigational Site
Jul 19, 2017

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719/GW642444 125/25
  • +3 more
  • Birmingham, Alabama
  • +96 more
Jan 18, 2018

Pulmonary Disease, Chronic Obstructive Trial in Harrow, London, Manchester (GW642444H (100mcg), , GW642444M (25, 100 & 400 mcg))

Completed
  • Pulmonary Disease, Chronic Obstructive
  • GW642444H (100mcg)
  • +2 more
  • Harrow, Middlesex, United Kingdom
  • +2 more
Aug 3, 2017

Pulmonary Disease, Chronic Obstructive Trial in London (GW642444M for 14 days)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • GW642444M for 14 days
  • London, United Kingdom
    GSK Investigational Site
Aug 2, 2017

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (GW642444 (25, 100 & 400 mcg/day), Salmeterol 50mcg)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • GW642444 (25, 100 & 400 mcg/day)
  • Salmeterol 50mcg
  • Wiesbaden, Hessen, Germany
  • +6 more
Sep 12, 2017

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GSK 573719 +GW642444 125/25
  • +5 more
  • Phoenix, Arizona
  • +30 more
Oct 9, 2017

Pulmonary Disease, Chronic Obstructive Trial in Fukuoka (GW642444, Placebo)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • GW642444
  • Placebo
  • Fukuoka, Japan
    GSK Investigational Site
Aug 1, 2017

Pulmonary Disease, Chronic Obstructive Trial in Stepney Green (GSK233705 and GW642444, GW642444, GSK233705)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • GSK233705 and GW642444
  • +3 more
  • Stepney Green, United Kingdom
    GSK Investigational Site
Jul 13, 2017

Pulmonary Disease, Chronic Obstructive Trial in Auchenflower, Clayton, Wellington (Placebo, GW642444, Magnesium Stearate)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • Placebo
  • +2 more
  • Auchenflower, Queensland, Australia
  • +2 more
Aug 8, 2017

Pulmonary Disease, Chronic Obstructive Trial in Randwick (Ketoconazole + GW642444M, Placebo + GW642444M)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • Ketoconazole + GW642444M
  • Placebo + GW642444M
  • Randwick, New South Wales, Australia
    GSK Investigational Site
Jul 13, 2017

Asthma Trial in United Kingdom (fluticasone furoate + vilanterol, inhaled corticosteroid with or without a long acting

Completed
Has Results
  • Asthma
  • fluticasone furoate + vilanterol
  • inhaled corticosteroid with or without a long acting beta2-agonist
  • Altrincham, Cheshire, United Kingdom
  • +179 more
Jul 26, 2018

Pulmonary Disease, Chronic Obstructive Trial in Prague 7 (Inhaled FF/ GW642444M (200/25mcg))

Completed
  • Pulmonary Disease, Chronic Obstructive
  • Inhaled FF/ GW642444M (200/25mcg)
  • Prague 7, Czechia
    GSK Investigational Site
Aug 1, 2017

Asthma Trial in Randwick (fluticasone furoate//GW642444, fluticasone furoate, GW642444)

Completed
  • Asthma
  • fluticasone furoate//GW642444
  • +2 more
  • Randwick, New South Wales, Australia
    GSK Investigational Site
Jun 9, 2017